This Week in Respiratory Health: Ageing & CF Research, Pivotal Trials, FDA Approvals & More
This week’s Respiratory Health Updates brings you essential insights into new collaborations, clinical trials, FDA approvals, and innovations in respiratory disease treatments. From tackling age-related challenges in cystic fibrosis to the launch of groundbreaking clinical studies, this is your go-to source for staying informed in the rapidly evolving respiratory health space.
🧪 Key highlights:
🤝 Cystic Fibrosis Trust Partners with BSRA to tackle age-related risks in CF patients, focusing on cancer and cardiovascular disease as nearly two-thirds of CF patients in the UK are over 16.
🚀 PureTech Launches Celea Therapeutics, a new biotech focused on advancing idiopathic pulmonary fibrosis (IPF) treatments with its lead candidate, deupirfenidone (LYT-100).
💊 PANTHERx Rare Selected to Dispense BRINSUPRI for non-CF bronchiectasis, marking the first FDA-approved treatment for this rare lung disease.
🏥 Amber Specialty Pharmacy Begins Distributing BRINSUPRI with nationwide dispensing and 24/7 pharmacist support for patients with non-CF bronchiectasis.
✅ NICE backs AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis (EGPA), providing patients in England with immediate access through interim funding.
🌬️ Apreo Health Begins Pivotal BREATHE-3 Trial for severe emphysema, enrolling 250 patients across 25 sites in the U.S. and Europe, with promising early results.
🇺🇸 FDA Approves Papzimeos (zopapogene imadenovec-drba), the first immunotherapy for recurrent respiratory papillomatosis (RRP), reducing the need for repeated surgeries in patients.
🔎 Alpha-1 Foundation Launches AlphaDetect to improve detection and awareness of Alpha-1 Antitrypsin Deficiency (AATD), aiming to address more than 90 percent of undiagnosed cases.
📉 GSK Korea Reports Positive COPD Triple Therapy Data, showing Trelegy Ellipta reduces moderate-to-severe COPD exacerbations by 18%, offering a better treatment option for patients.
⏸️ FDA Places Hold on BiomX BX004 Trial due to a third-party nebulizer device issue, while the trial continues in the EU for treating Pseudomonas aeruginosa infections in CF patients.
🇬🇧 Rein Therapeutics Wins UK Approval for IPF Phase 2 Trial of LTI-03, a novel peptide therapy for idiopathic pulmonary fibrosis, with results expected in 2026.
📢 Stay Ahead in Respiratory Research!
✅ Like, share, and subscribe for weekly updates on the latest respiratory breakthroughs.
#RespiratoryHealth #CysticFibrosis #IPF #RRP #EGPA #COPD #FDAApproval #PulmonaryCare #RespiratoryResearch #ClinicalTrials #HealthcareInnovation #BiotechNews #LucidQuest #MedicalAdvancements #Pulmonology #HealthTech